{"sourcedb":"DevicePMAs@therightstef","sourceid":"P980041_S001","text":"Approval for expanding the use of the afp immunoassay on the access 2 analyzer.  The device, as modified, will be marketed under the tradename access afp immunoassay system and is indicated for the quantitative determination of alpha-fetoprotein (afp) in:  1) human serum, as an aid in the management of patients with non-seminomatous testicular cancer.  2) maternal serum and amniotic fluid at 15 to 20 weeks gestation, to aid in the detection of fetal open neural tube defects (ontd).  Test results, when used in conjunction with ultrasonography, are safe and effective aids in the detection of fetal ontd.  The assay is intended for used in conjunction with other diagnostic tools such as ultrasound and amniography.","project":"consensus_PMA_Age_Indications"}